Escolar Documentos
Profissional Documentos
Cultura Documentos
background
Researchers used to believe that insulin was released in direct response to increasing blood glucose levels But then they noticed an odd thing:
Injecting glucose into the bloodstream doesnt raise insulin levels as much as giving the same amount of glucose by mouth.
India
Eli Lilly has Byetta (exenatide injection) [GLP-1 agonist] There are 6 DPP-4 inhibitors currently available
1. Sitagliptin (Merck & Co. Januvia), 2. Vildagliptin (Novartis, Galvus), 3. Saxagliptin (BMS, Onglyza), 4. Linagliptin (Boehringer Ingelheim, Tradjenta), 5. Dutogliptin (by Phenomix Corporation), 6. Gemigliptin (by LG Life Sciences,Korea)
Dipeptidyl peptidase-4 inhibitors are effective with a low incidence of hypoglycemia and no weight gain either as a single or combination therapy with lowering of
1. glycated hemoglobin, fasting and postprandial glucose levels.
HUMALOG
Humalog
Humalog is a mealtime insulin with a more rapid onset and a shorter duration of action than regular human insulin. When given subcutaneously, Humalog should be given within 15 minutes before or immediately after a meal and should generally be used in regimens that include an intermediate- or long-acting insulin.
Humalog
Humalog is engineered through recombinant DNA technology, the penultimate lysine and proline residues on the C-terminal end of the B-chain are reversed.
Humalog
This modification does not alter receptor binding, but blocks the formation of insulin dimers and hexamers. This permits larger amounts of active monomeric insulin to be immediately available for postprandial injections